Kinki University Hospital

Sayama, Osaka 589-8511

0 studies enrolling now · 3 studies all time

What they study most

Carcinoma, Renal Cell, Kidney Neoplasms, Solid Tumors

Studies at this site

• Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials — Completed
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed
• Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer — Completed